Previous 10 | Next 10 |
Cyclacel Pharmaceuticals, Inc. (CYCC) Q2 2020 Earnings Conference Call August 12, 2020 16:30 ET Company Participants Jan Medina - Investor Relations Spiro Rombotis - President and Chief Executive Officer Paul McBarron - Executive Vice President, Finance & Chief Operating Offi...
Cyclacel Pharmaceuticals (NASDAQ: CYCC ) : Q2 GAAP EPS of -$2.13 misses by $1.66 . Shares -6.8% . Press Release More news on: Cyclacel Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, ,
BERKELEY HEIGHTS, N.J., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today reported its financial results for the second ...
BERKELEY HEIGHTS, N.J., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce second quarter 2020 financial results ...
-- Characterization of fadraciclib published in peer-reviewed journal shows specificity against CDK2 and CDK9 and enablement of apoptosis of cancer cells driven by MCL1, cyclin E and/or MYC – -- Data builds on growing body of evidence indicating the promise of dual CDK2/9 i...
Penny Stocks To Watch In The Middle Of The Month Are you looking for some penny stocks to buy ? If you said yes, you’re not alone. This year we’ve seen so much attention on trading penny stocks and for good reason. If you look back at years-past, these small-cap stocks have go...
SIFCO (NYSEMKT: SIF ) +61% on Q2 results . More news on: SIFCO Industries, Inc., United Natural Foods, Inc., Cyclacel Pharmaceuticals, Inc., Stocks on the move, , Read more ...
Cyclacel Pharmaceuticals, Inc. (CYCC) Q1 2020 Results Earnings Conference Call May 12, 2020, 04:30 PM ET Company Participants Jan Medina - Investor Relations Spiro Rombotis - President and Chief Executive Officer Paul McBarron - Executive Vice President, Finance and Chief Operati...
Cyclacel Pharmaceuticals (NASDAQ: CYCC ): Q1 GAAP EPS of -$2.77 beats by $0.13 . Cash and cash equivalents of $8.9M Press Release More news on: Cyclacel Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, ,
- Conference Call Scheduled May 12, 2020 at 4:30 p.m. ET - - Following Recent Financing Cash Runway to End of 2022 - BERKELEY HEIGHTS, N.J., May 12, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Com...
News, Short Squeeze, Breakout and More Instantly...
Cyclacel Pharmaceuticals Inc. Company Name:
CYCC Stock Symbol:
NASDAQ Market:
Cyclacel Pharmaceuticals Inc. Website:
BERKELEY HEIGHTS, N.J., June 26, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced the receipt of a notice from the European ...
- Novel CDK2/9 inhibitor fadraciclib induces anaphase catastrophe, a novel cancer-specific mechanism of action - BERKELEY HEIGHTS, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”...
- Clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing proof of concept study in patients with solid tumors and lymphoma - BERKELEY HEIGHTS, N.J., June 03, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP;...